069620.KS
Daewoong pharmaceutical Co.,Ltd [069620.KS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
069620.KS Stock Summary
Top 10 Correlated ETFs
069620.KS
Top 10 Correlated Stocks
069620.KS
In the News
069620.KS Financial details
Company Rating
Buy
Market Cap
1201.26B
Income
49.28B
Revenue
1332.28B
Book val./share
59673.48
Cash/share
13087.6
Dividend
600
Dividend %
0.58%
Employees
1.72K
Optionable
No
Shortable
Yes
Earnings
30 Oct 2023
P/E
24.26
Forward P/E
-
PEG
2.54
P/S
0.9
P/B
1.74
P/C
7.94
P/FCF
68.24
Quick Ratio
0.62
Current Ratio
1.08
Debt / Equity
0.6
LT Debt / Equity
0.21
-
-
EPS (TTM)
4.35K
EPS next Y
-
EPS next Q
-
EPS this Y
77.89%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
4.41%
Revenue Q/Q
8.62%
EPS Q/Q
55.93%
-
-
-
-
SMA20
1.04%
SMA50
13.06%
SMA100
-1.23%
Inst Own
-
Inst Trans
-
ROA
3%
ROE
8%
ROC
0.1%
Gross Margin
51%
Oper. Margin
8%
Profit Margin
4%
Payout
2%
Shs Outstand
11.51M
Shs Float
5.38M
-
-
-
-
Target Price
-
52W Range
88300.0-173000.0
52W High
-39.94%
52W Low
+17.67%
RSI
46
Rel Volume
0.33
Avg Volume
37.18K
Volume
12.26K
Perf Week
-4.24%
Perf Month
-6.14%
Perf Quarter
0.39%
Perf Half Y
-0.57%
-
-
-
-
Beta
1.01762
-
-
Volatility
1902.52%, 2313.17%
Prev Close
-0.48%
Price
103900
Change
-0.1%
069620.KS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 99.93K | 107.87K | 98.98K | 104.78K | 120.06K | |
| Net income per share | -1.47K | 2.13K | 2.26K | 2.24K | 3.96K | |
| Operating cash flow per share | 4.6K | 5.58K | 9.47K | 3.63K | 11.09K | |
| Free cash flow per share | -926.43 | 725.99 | 3.87K | -3.16K | 460.1 | |
| Cash per share | 12.85K | 12.58K | 16.61K | 15.79K | 13.19K | |
| Book value per share | 47.87K | 50.31K | 51.67K | 52.12K | 57.02K | |
| Tangible book value per share | 44.4K | 45.65K | 48.44K | 43.37K | 44.57K | |
| Share holders equity per share | 47.87K | 50.31K | 51.67K | 52.12K | 57.02K | |
| Interest debt per share | 38.41K | 39.05K | 42.79K | 41.43K | 42.68K | |
| Market cap | 1914.62B | 1419.24B | 1759.46B | 1628.58B | 1711.33B | |
| Enterprise value | 2236.14B | 1780.07B | 2132.85B | 1998.37B | 2055.09B | |
| P/E ratio | -126.36 | 64.49 | 72.86 | 66.04 | 40.51 | |
| Price to sales ratio | 1.86 | 1.27 | 1.67 | 1.41 | 1.34 | |
| POCF ratio | 40.31 | 24.64 | 17.42 | 40.72 | 14.48 | |
| PFCF ratio | -200.23 | 189.4 | 42.62 | -46.8 | 348.84 | |
| P/B Ratio | 3.87 | 2.73 | 3.19 | 2.84 | 2.81 | |
| PTB ratio | 3.87 | 2.73 | 3.19 | 2.84 | 2.81 | |
| EV to sales | 2.17 | 1.6 | 2.02 | 1.73 | 1.61 | |
| Enterprise value over EBITDA | 27.06 | 21.01 | 35 | 29.18 | 21.23 | |
| EV to operating cash flow | 47.08 | 30.9 | 21.12 | 49.97 | 17.38 | |
| EV to free cash flow | -233.85 | 237.55 | 51.66 | -57.42 | 418.91 | |
| Earnings yield | -0.01 | 0.02 | 0.01 | 0.02 | 0.02 | |
| Free cash flow yield | 0 | 0.01 | 0.02 | -0.02 | 0 | |
| Debt to equity | 0.78 | 0.76 | 0.81 | 0.78 | 0.73 | |
| Debt to assets | 0.32 | 0.32 | 0.33 | 0.31 | 0.29 | |
| Net debt to EBITDA | 3.89 | 4.26 | 6.13 | 5.4 | 3.55 | |
| Current ratio | 1.4 | 2.01 | 1.62 | 1.14 | 1.16 | |
| Interest coverage | 2.56 | 4.43 | 1.6 | 2.69 | 6.79 | |
| Income quality | -3.08 | 2 | 4.18 | 1.32 | 3.02 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | -0.41 | 0.28 | 0.26 | 0.26 | 0.19 | |
| Sales general and administrative to revenue | 0.03 | 0.02 | 0.02 | 0.02 | 0.02 | |
| Research and developement to revenue | 0.11 | 0.1 | 0.11 | 0.11 | 0.13 | |
| Intangibles to total assets | 0.12 | 0.13 | 0.13 | 0.16 | 0.17 | |
| Capex to operating cash flow | -1.2 | -0.87 | -0.59 | -1.87 | -0.96 | |
| Capex to revenue | -0.06 | -0.05 | -0.06 | -0.06 | -0.09 | |
| Capex to depreciation | -1.11 | -1.25 | -1.46 | -1.83 | -2.85 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 39.77K | 49.13K | 51.31K | 51.27K | 71.29K | |
| ROIC | 0.69 | 0.06 | 0.03 | 0.04 | 0.05 | |
| Return on tangible assets | -0.01 | 0.02 | 0.02 | 0.02 | 0.03 | |
| Graham Net | -22.17K | -22.16K | -25.88K | -29.16K | -40.31K | |
| Working capital | 148.27B | 264.18B | 201.6B | 64.23B | 76.14B | |
| Tangible asset value | 458.24B | 471.23B | 516.51B | 477.24B | 475.22B | |
| Net current asset value | -84.37B | -83.49B | -143.31B | -187.88B | -273.15B | |
| Invested capital | 0.78 | 0.76 | 0.81 | 0.78 | 0.73 | |
| Average receivables | 188.1B | 204.35B | 196.01B | 174.86B | 185.29B | |
| Average payables | 60.85B | 69.48B | 77.74B | 74.82B | 77.13B | |
| Average inventory | 188.03B | 183.32B | 175.79B | 174.51B | 191.89B | |
| Days sales outstanding | 68 | 70.98 | 60.69 | 55.16 | 55.99 | |
| Days payables outstanding | 36.57 | 44.08 | 47.26 | 42.52 | 47.48 | |
| Days of inventory on hand | 111.02 | 102.07 | 104.36 | 105.05 | 118.83 | |
| Receivables turnover | 5.37 | 5.14 | 6.01 | 6.62 | 6.52 | |
| Payables turnover | 9.98 | 8.28 | 7.72 | 8.58 | 7.69 | |
| Inventory turnover | 3.29 | 3.58 | 3.5 | 3.47 | 3.07 | |
| ROE | -0.03 | 0.04 | 0.04 | 0.04 | 0.07 | |
| Capex per share | -5.53K | -4.85K | -5.6K | -6.8K | -10.63K |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
| Metric | History | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 29.1K | 29.98K | 29.61K | 28.85K | 30.43K | |
| Net income per share | 1.58K | 1.85K | -1.03K | 1.38K | 2.15K | |
| Operating cash flow per share | 1.41K | 2.76K | 4.3K | 2.26K | 2.85K | |
| Free cash flow per share | 46.56 | 75.52 | 915.54 | -576.11 | 1.13K | |
| Cash per share | 15.41K | 16.49K | 12.71K | 16K | 13.09K | |
| Book value per share | 55.35K | 56.87K | 54.93K | 59.51K | 59.67K | |
| Tangible book value per share | 44.23K | 45.28K | 42.93K | 46.28K | 47.04K | |
| Share holders equity per share | 55.35K | 56.87K | 54.93K | 59.51K | 59.67K | |
| Interest debt per share | 39.85K | 40.86K | 40.69K | 39.67K | 35.87K | |
| Market cap | 1953.72B | 1748.93B | 1776.67B | 1175.53B | 1108.23B | |
| Enterprise value | 2278.34B | 2064.87B | 2120.43B | 1476.53B | 1408.55B | |
| P/E ratio | 27.96 | 21.33 | -39.06 | 19.07 | 11.2 | |
| Price to sales ratio | 6.07 | 5.27 | 5.42 | 3.65 | 3.16 | |
| POCF ratio | 125.48 | 57.23 | 37.33 | 46.58 | 33.85 | |
| PFCF ratio | 3.79K | 2.09K | 175.31 | -182.6 | 85.34 | |
| P/B Ratio | 3.19 | 2.78 | 2.92 | 1.77 | 1.61 | |
| PTB ratio | 3.19 | 2.78 | 2.92 | 1.77 | 1.61 | |
| EV to sales | 7.07 | 6.22 | 6.47 | 4.58 | 4.02 | |
| Enterprise value over EBITDA | 57.29 | 51.63 | -177.41 | 9.29 | 7.69 | |
| EV to operating cash flow | 146.33 | 67.57 | 44.55 | 58.5 | 43.02 | |
| EV to free cash flow | 4.42K | 2.47K | 209.23 | -229.36 | 108.46 | |
| Earnings yield | 0.01 | 0.01 | -0.01 | 0.01 | 0.02 | |
| Free cash flow yield | 0 | 0 | 0.01 | -0.01 | 0.01 | |
| Debt to equity | 0.73 | 0.71 | 0.73 | 0.66 | 0.6 | |
| Debt to assets | 0.3 | 0.29 | 0.29 | 0.27 | 0.25 | |
| Net debt to EBITDA | 8.16 | 7.9 | -28.76 | 1.89 | 1.64 | |
| Current ratio | 1.38 | 1.34 | 1.16 | 1.19 | 1.08 | |
| Interest coverage | -5.52 | 9.13 | 3.39 | 17.07 | 0 | |
| Income quality | 0.96 | 1.44 | -4.19 | 1.83 | 1.14 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0.38 | 0 | -0.07 | 0 | 0 | |
| Sales general and administrative to revenue | 0.02 | 0.02 | 0.02 | 0.42 | 0.41 | |
| Research and developement to revenue | 0.12 | 0.12 | 0.14 | 0.14 | 0 | |
| Intangibles to total assets | 0.17 | 0.17 | 0.17 | 0.17 | 0.17 | |
| Capex to operating cash flow | -0.97 | -0.97 | -0.79 | -1.26 | -0.6 | |
| Capex to revenue | -0.05 | -0.09 | -0.11 | -0.1 | -0.06 | |
| Capex to depreciation | -1.55 | -3 | -3.7 | -3.1 | -1.82 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 44.33K | 48.68K | 35.63K | 42.97K | 53.73K | |
| ROIC | 0.02 | 0.02 | 0 | 0.01 | 0.03 | |
| Return on tangible assets | 0.01 | 0.02 | -0.01 | 0.01 | 0.02 | |
| Graham Net | -31.87K | -32.71K | -38.83K | -38.06K | -36.71K | |
| Working capital | 157.3B | 146.92B | 76.14B | 93.44B | 40.6B | |
| Tangible asset value | 489.63B | 501.19B | 475.22B | 517.17B | 541.33B | |
| Net current asset value | -190.03B | -198.14B | -273.15B | -251.54B | -250.13B | |
| Invested capital | 0.73 | 0.71 | 0.73 | 0.66 | 0.6 | |
| Average receivables | 170.82B | 179.63B | 186.77B | 184.97B | 176.44B | |
| Average payables | 85.43B | 91.39B | 89.05B | 95.02B | 98.1B | |
| Average inventory | 191.69B | 204.84B | 209.57B | 218.87B | 228.06B | |
| Days sales outstanding | 50.88 | 48.05 | 53.91 | 48.45 | 46.08 | |
| Days payables outstanding | 49.87 | 52.19 | 45.74 | 58.73 | 48.24 | |
| Days of inventory on hand | 112.84 | 115.96 | 114.48 | 126.11 | 122.34 | |
| Receivables turnover | 1.77 | 1.87 | 1.67 | 1.86 | 1.95 | |
| Payables turnover | 1.8 | 1.72 | 1.97 | 1.53 | 1.87 | |
| Inventory turnover | 0.8 | 0.78 | 0.79 | 0.71 | 0.74 | |
| ROE | 0.03 | 0.03 | -0.02 | 0.02 | 0.04 | |
| Capex per share | -1.36K | -2.69K | -3.38K | -2.83K | -1.72K |
069620.KS Frequently Asked Questions
What is Daewoong pharmaceutical Co.,Ltd stock symbol ?
Daewoong pharmaceutical Co.,Ltd is a KR stock and trading under the symbol 069620.KS
What is Daewoong pharmaceutical Co.,Ltd stock quote today ?
Daewoong pharmaceutical Co.,Ltd stock price is $103900 today.
Is Daewoong pharmaceutical Co.,Ltd stock public?
Yes, Daewoong pharmaceutical Co.,Ltd is a publicly traded company.
Company Profile
- Volume Average 37.18K
- Market Capitalization 1201.26B
- Employee 1.72K
- CEO Mr. Seng-Ho Jeon
- Headquarters Seoul,KR
- IPO Date 2005-09-29
-
Website
https://www.daewoong.com 
Daewoong Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplements, and muti-vitamins. The company also provides COVID-19 PCR kit, COVID-19 IgG/IgM RDT, and viral transport medium medical devices. The company was founded in 1945 and is headquartered in Seoul, South Korea.
